Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, UK.
Toxicol Sci. 2012 May;127(1):150-8. doi: 10.1093/toxsci/kfs080. Epub 2012 Feb 13.
Adverse drug reactions represent a major stumbling block to drug development and those with an immune etiology are the most difficult to predict. We have developed an in vitro T-cell priming culture method using peripheral blood from healthy volunteers to assess the allergenic potential of drugs. The drug metabolite nitroso sulfamethoxazole (SMX-NO) was used as a model drug allergen to establish optimum assay conditions. Naive T cells were cocultured with monocyte-derived dendritic cells at a ratio of 25:1 in the presence of the drug for a period of 8 days, to expand the number of drug-responsive T cells. The T cells were then incubated with fresh dendritic cells, and drug and their antigen responsiveness analyzed using readouts for proliferation, cytokine secretion, and cell phenotype. All five volunteers showed dose-dependent proliferation as measured by 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester content and by (3)H-thymidine uptake. CD4 T cells that had divided in the presence of SMX-NO had changed from a naive phenotype (CD45RA+) to a memory phenotype (CD45RO+). These memory T cells expressed the chemokine receptors CCR2, CCR4, and CXCR3 suggesting a mixture of T(H)1 and T(H)2 cells in the responding population, with a propensity for homing to the skin. Drug stimulation was also associated with the secretion of a mixture of T(H)1 cytokines (interferon γ) and T(H)2 cytokines (interleukin [IL]-5 and IL-13) as detected by ELISpot. We are currently developing this approach to investigate the allergenic potential of other drugs, including those where an association between specific human leucocyte antigen alleles and susceptibility to an immunological reaction has been established.
药物不良反应是药物开发的主要障碍,其中具有免疫病因的药物最难预测。我们开发了一种使用健康志愿者外周血的体外 T 细胞启动培养方法,以评估药物的变应原潜力。将药物代谢物亚硝基磺胺甲恶唑 (SMX-NO) 用作模型药物变应原,以建立最佳测定条件。将幼稚 T 细胞与单核细胞衍生的树突状细胞以 25:1 的比例在药物存在下共培养 8 天,以扩增对药物有反应的 T 细胞数量。然后将 T 细胞与新鲜的树突状细胞孵育,并使用增殖、细胞因子分泌和细胞表型的读出物分析药物和其抗原反应性。所有五名志愿者均表现出剂量依赖性增殖,如 5-(和 6)-羧基荧光素二乙酸琥珀酰亚胺酯含量和 (3)H-胸苷摄取所测。在 SMX-NO 存在下分裂的 CD4 T 细胞已从幼稚表型 (CD45RA+) 转变为记忆表型 (CD45RO+)。这些记忆 T 细胞表达趋化因子受体 CCR2、CCR4 和 CXCR3,表明反应人群中存在 T(H)1 和 T(H)2 细胞的混合物,并且倾向于归巢到皮肤。药物刺激还与 T(H)1 细胞因子 (干扰素 γ) 和 T(H)2 细胞因子 (白细胞介素 [IL]-5 和 IL-13) 的混合物分泌相关,通过 ELISpot 检测到。我们目前正在开发这种方法来研究其他药物的变应原潜力,包括那些已经确定特定人类白细胞抗原等位基因与免疫反应易感性之间存在关联的药物。